2024
Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.Peer-Reviewed Original ResearchChimeric antigen receptor T-cell therapyB-cell lymphomaRelapsed/refractory B-cell lymphomaT-cell therapyCAR-T administrationCAR-T productsMedian total costCommercially insured patientsReal-world costsMedian costOut-of-pocket copaymentsCost of careLymphomaMonthly costTherapyPatientsProduct acquisitionFinancial outcomesHigher upfront cost
2022
Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas
Koh MJ, Merrill MH, Koh MJ, Stuver R, Alonso CD, Foss FM, Mayor AM, Gill J, Epeldegui M, Cachay E, Thorne JE, Silverberg MJ, Horberg MA, Althoff K, Nijhawan AE, McGinnis KA, Lee JS, Rabkin CS, Napravnik S, Li J, Castilho JL, Shen C, Jain S. Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas. Blood Advances 2022, 6: 1420-1431. PMID: 35026839, PMCID: PMC8905704, DOI: 10.1182/bloodadvances.2021006208.Peer-Reviewed Original ResearchConceptsT-cell lymphomaAnaplastic large cell lymphomaB-cell lymphomaHodgkin's lymphomaNorth American AIDS Cohort CollaborationNK/T-cell lymphomaPrimary central nervous system lymphomaModern antiretroviral therapy (ART) eraCentral nervous system lymphomaLarge B-cell lymphomaAntiretroviral therapy eraComprehensive Oncology MeasuresMature T-cell lymphomasNervous system lymphomaLarge cell lymphomaT-cell malignanciesMature T cellsCohort CollaborationTherapy eraOverall survivalSystem lymphomaHistologic confirmationLymphoma treatmentT cellsComparative outcomes
2021
Comparative Analysis of Mature T-Cell and NK/T-Cell Lymphomas in Patients with and without HIV: Results from the NA-Accord and Complete Cohorts
Koh M, Merrill M, Koh M, Stuver R, Alonso C, Foss F, Mayor A, Gill M, Epeldegui M, Cachay E, Thorne J, Silverberg M, Horberg M, Atlhoff K, Nijhawan A, McGinnis K, Rabkin C, Napravnik S, Shen C, Jain S. Comparative Analysis of Mature T-Cell and NK/T-Cell Lymphomas in Patients with and without HIV: Results from the NA-Accord and Complete Cohorts. Blood 2021, 138: 1380. DOI: 10.1182/blood-2021-147837.Peer-Reviewed Original ResearchNK/T-cell lymphomaT-cell lymphomaB-cell lymphomaNA-ACCORDViral loadBurkitt's lymphomaLymphoma diagnosisCurrent antiretroviral therapy eraWorse median overall survivalPeripheral T-cell lymphomaAnaplastic large cell lymphomaLarge B-cell lymphomaAntiretroviral therapy eraBaseline clinical characteristicsMedian overall survivalMulticenter cohort studyOutcomes of patientsSpeakers bureauChronic kidney diseasePrimary CNS lymphomaYear of diagnosisCommon histological subtypeMature T-cell lymphomasSurvival of patientsLarge observational cohort
2020
Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaPola-BRR DLBCLRefractory diffuse large B-cell lymphomaLonger progression-free survivalRecent phase II trialDiffuse large B-cell lymphomaProgression-free survivalTransplant-ineligible patientsPhase II trialUS payer perspectiveCost-effectiveness ratioII trialOverall survivalTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessIncremental costPolatuzumabRituximabLymphomaDLBCL
2015
The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project
Bellei M, Nabhan C, Pesce EA, Conte L, Vose JM, Foss F, Federico M. The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project. Current Hematologic Malignancy Reports 2015, 10: 448-455. PMID: 26449717, DOI: 10.1007/s11899-015-0291-0.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell ProjectLymphoma RegistryCell lymphomaManagement of PTCLFuture clinical trialsOptimal therapeutic strategyT-cell lymphomaB-cell lymphomaPoor prognosisLymphoma treatmentLarge registriesClinical trialsLymphoid malignanciesTherapeutic strategiesNew agentsRegistryHeterogeneous groupPrognosisLymphoma
2013
Polymorphisms in DNA repair pathway genes, body mass index, and risk of non‐Hodgkin lymphoma
Chen Y, Zheng T, Lan Q, Kim C, Qin Q, Foss F, Chen X, Holford T, Leaderer B, Boyle P, Wang C, Dai M, Liu Z, Ma S, Chanock SJ, Rothman N, Zhang Y. Polymorphisms in DNA repair pathway genes, body mass index, and risk of non‐Hodgkin lymphoma. American Journal Of Hematology 2013, 88: 606-611. PMID: 23619945, PMCID: PMC3902049, DOI: 10.1002/ajh.23463.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBody Mass IndexCase-Control StudiesDNA RepairDNA-Binding ProteinsExodeoxyribonucleasesFemaleGenotypeHumansLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMiddle AgedPolymorphism, GeneticRecQ HelicasesRisk FactorsUbiquitin-Protein LigasesWerner Syndrome HelicaseXeroderma Pigmentosum Group D ProteinX-ray Repair Cross Complementing Protein 1ConceptsBody mass indexNon-Hodgkin lymphomaDNA repair pathway genesCT/TTMass indexNHL riskPopulation-based case-control studyRisk of NHLDiffuse large B-cell lymphomaGT/TT genotypesLarge B-cell lymphomaAC/CCT-cell lymphomaCase-control studyB-cell lymphomaConnecticut womenTT genotypeGG genotypePathway genesLymphomaCommon genetic variationWomenRiskSignificant interaction
2012
Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non‐Hodgkin lymphoma
Bi X, Zheng T, Lan Q, Xu Z, Chen Y, Zhu G, Foss F, Kim C, Dai M, Zhao P, Holford T, Leaderer B, Boyle P, Deng Q, Chanock SJ, Rothman N, Zhang Y. Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non‐Hodgkin lymphoma. American Journal Of Hematology 2012, 87: 766-769. PMID: 22649007, PMCID: PMC3576861, DOI: 10.1002/ajh.23244.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaAG/AA genotypesHistory of transfusionBlood transfusionB-cell lymphomaGG genotypeAA genotypePopulation-based case-control studyRisk of NHLGenetic polymorphismsT-cell lymphomaCase-control studyDecreased riskNHL overallIL10RA geneConnecticut womenNHL riskTh2 cytokine genesTransfusionLymphomaCytokine genesTNFWomenRiskIL10RA
2011
Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond
Foss F. Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond. Therapeutic Advances In Hematology 2011, 2: 161-173. PMID: 23556087, PMCID: PMC3573405, DOI: 10.1177/2040620711408491.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaT-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaFirst-line therapySubset of patientsAggressive clinical courseNon-Hodgkin lymphomaB-cell lymphomaHistone deacetylase inhibitorsCurative optionRefractory diseaseClinical courseCell transplantationTherapeutic advancesNew agentsTreatment approachesLymphomaDeacetylase inhibitorsMonoclonal antibodiesHeterogeneous groupProteasome inhibitorsNucleoside analoguesPatientsTherapy
2010
Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.
Armitage JO, Hsi ED, Foss FM. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clinical Advances In Hematology And Oncology 2010, 8: 1-15. PMID: 21491667.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaPTCL subtypesTherapeutic regimensDisease state awarenessAggressive disease courseT-cell markersB-cell lymphomaMost patientsRefractory diseaseDisease courseIndolent courseAggressive diseaseLymphoproliferative disordersPoor prognosisTherapeutic overviewEffective treatmentProper diagnosisLymphomaRegimensSubtypesHeterogeneous groupPatientsPrognosisDiseaseCytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma
Chen Y, Zheng T, Lan Q, Foss F, Kim C, Chen X, Dai M, Li Y, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y. Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood 2010, 117: 585-590. PMID: 20952689, PMCID: PMC3031482, DOI: 10.1182/blood-2010-07-295097.Peer-Reviewed Original ResearchConceptsBody mass indexNon-Hodgkin lymphomaAG/GGB-cell lymphomaMass indexCommon B-cell lymphoma subtypesSmall lymphocytic lymphoma/chronic lymphocytic leukemiaRisk of NHLMarginal zone B-cell lymphomaCT/TT genotypesB-cell lymphoma subtypesT-cell lymphomaCase-control studyCT/TTChronic lymphocytic leukemiaNHL overallConnecticut womenNHL riskLymphocytic leukemiaLymphoma subtypesTh2 cytokine genesFollicular lymphomaTT genotypeSignificant interactionLymphomaEnhancing Existing Approaches to Peripheral T-Cell Lymphoma
Foss FM. Enhancing Existing Approaches to Peripheral T-Cell Lymphoma. Seminars In Hematology 2010, 47: s8-s10. PMID: 20359584, DOI: 10.1053/j.seminhematol.2010.01.012.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaFirst-line therapyT-cell lymphomaNational Comprehensive Cancer Network practice guidelinesEffective first-line therapyStandard treatment optionSame treatment regimenB-cell lymphomaPTCL patientsTreatment regimenDenileukin diftitoxConventional therapyHistopathologic subtypeTreatment optionsNovel agentsPractice guidelinesLymphomaChemotherapy platformTherapyPatientsOutcomesDiftitoxRegimenTransplantSubtypes
2009
Alcohol consumption and non-Hodgkin lymphoma survival
Han X, Zheng T, Foss FM, Ma S, Holford TR, Boyle P, Leaderer B, Zhao P, Dai M, Zhang Y. Alcohol consumption and non-Hodgkin lymphoma survival. Journal Of Cancer Survivorship 2009, 4: 101-109. PMID: 20039144, PMCID: PMC3141078, DOI: 10.1007/s11764-009-0111-4.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaNon-Hodgkin lymphomaAlcohol consumptionHazard ratioNHL subtypesNHL survivalNon-Hodgkin lymphoma survivalCox proportional hazards modelLarge B-cell lymphomaDisease-free survivalBetter overall survivalKaplan-Meier methodModerate alcohol drinkersProportional hazards modelB-cell lymphomaLower death ratesIntroductionEpidemiological studiesFree survivalOverall survivalNHL patientsAlcohol drinkersIncident casesMethodsA cohortAlcohol drinkingDLBCL patients
2002
Lymphoma of the Skin
Connors JM, Hsi ED, Foss FM. Lymphoma of the Skin. Hematology 2002, 2002: 263-282. PMID: 12446427, DOI: 10.1182/asheducation-2002.1.263.Peer-Reviewed Original ResearchConceptsT-cell lymphomaCutaneous lymphomasNew World Health Organization classification systemCutaneous anaplastic large cell lymphomaWorld Health Organization classification systemPeripheral T-cell lymphomaCutaneous T-cell lymphomaAnaplastic large cell lymphomaCurrent optimal treatmentLarge cell lymphomaB-cell lymphomaMycosis fungoidesSkin lymphomaHodgkin's lymphomaOptimal treatmentStandard treatmentCell lymphomaEffective modalityLymphoma entitiesTreatment approachesLymphomaLymphoma classificationDiseaseSkinTreatment